NeurOrbis Ventures LLC
AI-Powered Technology Ecosystem Intelligence

Understand an Entire Technology Landscape.
Make Better Decisions. Faster.

Explore patents, scientific literature, clinical trials, companies, market intelligence, licensing, and news—all through one AI-powered platform built for your technology domain.

Purpose-built intelligence platforms for high-impact technology domains.

Drug Discovery
Batteries
Artificial Intelligence
Biotechnology
Advanced Materials

Built for |

NeurOrbis
Search by title, number, assignee, claims...⌘K
KB
Overview
Drug Intelligence
Patent Intelligence
Scientific Literature
Clinical Trials
Company Intelligence
Market Intelligence
News & Regulatory
AI Workspace
Saved Filters
Problem
Obesity
Solution
Oral Delivery
Indication
Type 2 Diabetes
Mechanism
GLP-1 Agonists
Filters
Drug Assets
248
+12%vs last 3M
Patent Families
18,845
+8%vs last 3M
Clinical Trials
1,253
+15%vs last 3M
Companies
487
+9%vs last 3M
Patent Filing Trend
All Years
FamiliesPatent Filings
8K6K4K2K
2015201620172018201920202021202220232024
Publications
24,531
+14%vs last 3M
News Mentions
8,742
+11%vs last 3M
Licensing Deals
387
+6%vs last 3M
Geographic Distribution(by Patent Families)
North America42%
Europe28%
Asia Pacific20%
Rest of World10%
Top Companies by Patent Families
View all
NNovo Nordisk
3.2k
EEli Lilly
2.6k
AAmgen
1.8k
AAstraZeneca
1.4k
BBoehringer Ingelheim
1.1k
AI AssistantBeta
Hello! I'm NeurOrbis AI. Ask me anything about this landscape.
Which companies are leading in oral GLP-1 patents?
Show latest Phase III assets for obesity
Compare patenting activity: Lilly vs Novo Nordisk
Ask a question...
Recent Intelligence
View all
May 07, 2025
Novo Nordisk reports Q1 2025 results; expands oral GLP-1 program
Company
May 06, 2025
Lilly initiates Phase III trial for orforglipron in obesity
Clinical Trial
May 05, 2025
FDA grants Fast Track to new dual agonist for T2D
Regulatory
Technology Platforms

Purpose-Built Intelligence Platforms

Live, in-development, and on-request platforms for high-impact domains.

Featured Platform

GLP-1 Ecosystem Intelligence

LIVE

The most comprehensive intelligence platform for the incretin (GLP-1) space.

Patent Landscape & Analytics
Scientific Literature Intelligence
Clinical Trials & Drug Pipeline
Company & Competitor Intelligence
Licensing & Deal Tracking
Market Intelligence & Forecasts
Regulatory & News Monitoring
AI Assistant for Deep Insights
GLP-1 Therapeutic Landscape
GLP-1 RAsDual AgonistsTriple Agonists
Oral Small MoleculesOral/Dual MoleculesAmylin Analogs
Drug Pipeline Overview
142
Active Programs
Indication Focus
Obesity46%
T2D28%
NASH/MASH16%
CV / Other6%
Top Mechanisms
GLP-1R Agonist34(34%)
GLP-1/GIP Dual Agonist26(26%)
GLP-1/GIP/GCGR Triple12(12%)
GLP-1R Oral30(30%)
Amylin Analog10(10%)
Other / Novel10(10%)

Solid-State Battery Intelligence

COMING SOON

Comprehensive intelligence on solid-state batteries and next-gen energy storage.

AI in Drug Discovery Intelligence

IN DEVELOPMENT

AI-driven insights across targets, modalities and discovery technologies.

Custom Technology Intelligence

AVAILABLE ON REQUEST

Custom intelligence solutions for your technology domain.

Why Neurorbis

Why Teams Choose NeurOrbis

Five reasons research, IP, and strategy teams trust NeurOrbis as their connected intelligence layer.

Multi-Source Intelligence

Patents, literature, trials, companies, market & news in one place

Human-Curated & AI-Powered

Expert curation with advanced AI for deeper, faster insights

Always Up-to-Date

Continuous monitoring across global sources

Actionable Insights

From data to decisions that drive impact

Secure & Enterprise Ready

Role-based access, SSO & data security

Why Neurorbis

From Fragmented Research to
Connected Intelligence

NeurOrbis unifies the world's most critical intelligence sources and transforms disconnected data into insights that drive better decisions, faster.

Without Neurorbis

Fragmented. Manual. Time-consuming.

!
!
!
!
!
!
Patent Databases
Scientific Literature
Market Reports
Clinical Trials
Company Information
Spreadsheets & Files
News & Updates
Your Team
Data silos and disconnected sources
Outdated reports and stale insights
Manual searching across multiple tools
Hard to see the full technology picture
Neurorbis
With Neurorbis

Connected. AI-Powered. Always Current.

Patents
25,418
Publications
18,342
Clinical Trials
2,193
Companies
6,842
Technology Trend Over Time
201920202021202220232024
Top Companies by Activity
NeuroShield
MedNova
AutoSense
BioNova AI Systems
BioForge Insights
Technology Map
Recent Insights
New GLP-1 receptor patent cluster shows acceleration in oral delivery.
Neurocompounds are expanding in oral peptide delivery formulations.
Clinical trials for combination therapies are rising across markets.
View all insights →
Unified Intelligence
Everything connected in one platform.
AI-Powered Discovery
Ask questions. Get answers. Uncover what matters.
Expert-Curated
Domain-specific taxonomies and tagging for accuracy
Always Current
Continuous updates across all sources
Built for Teams
Collaborate, annotate and make aligned decisions
360° Technology View
See the full innovation landscape and make strategic moves
Turn information into intelligence. Make decisions with confidence.
Explore the Platform
Ready to explore your technology ecosystem?
Request a Demo
AI-Powered Research Assistant

Ask Your Technology Anything

Explore patents, scientific literature, clinical trials, market intelligence, companies, licensing, and news through one AI-powered research assistant. Every answer is connected to its supporting evidence.

Ask a question about any technology...

Try these questions

Data Sources

Patent IntelligenceScientific LiteratureClinical TrialsCompany IntelligenceMarket IntelligenceNews Module
Secure. Private. Enterprise-ready.
AI Insight
Today, 10:24 AM

Several companies are actively developing oral GLP-1 therapies. Novo Nordisk currently leads with commercialized oral semaglutide, while Eli Lilly, Pfizer and Structure Therapeutics are exploring differentiated approaches.

Recent patent filings indicate increasing activity around oral delivery technologies, absorption enhancers and combination therapies.

Patent Insight
Recent filings focus on oral peptide stabilization and absorption enhancers.
124 Patents
Scientific Evidence
Novel carrier systems and permeability enhancers.
86 Publications
Clinical Evidence
Multiple Phase III trials evaluating oral GLP-1 therapies.
42 Clinical Trials
Company & Licensing
Strategic partnerships and licensing activity.
31 Companies / Deals
Market Perspective
Growing commercial adoption and expansion.
18 Market Reports
News & Regulatory
Recent approvals and regulatory milestones.
12 News Items

Evidence Mix

Patent Intelligence: 39%Scientific Literature: 27%Clinical Trials: 13%Company Intelligence: 10%Market Intelligence: 7%News Module: 4%
313Total Sources
Patent Intelligence39%
Scientific Literature27%
Clinical Trials13%
Company Intelligence10%
Market Intelligence7%
News Module4%
Confidence Level
High

Generated using evidence from six connected intelligence sources.

Answers are generated using connected intelligence across multiple data sources.
Every insight is traceable to its supporting evidence.

Explore AI Research Assistant
Who Uses Neurorbis

Built for Every Innovation Team

Whether you're discovering new technologies, protecting innovation, evaluating investments, or monitoring competitors, NeurOrbis delivers connected intelligence tailored to your role.

Accelerate Discovery. Find What's Next.

Identify emerging technologies, validate scientific hypotheses, uncover white-space opportunities, and prioritize high-impact innovations using connected intelligence across patents, literature, trials, market and competitive data.

Key Questions We Answer

  • What technologies and mechanisms are growing fastest?
  • Which problems remain unsolved?
  • Which solutions are gaining traction?
  • What does the competitive landscape look like?
  • Which companies and research groups are leading innovation?

Outcomes You Achieve

  • Prioritize high-potential R&D programs
  • Accelerate early-stage discovery
  • Reduce duplication of research
  • Stay ahead of scientific trends
  • Build stronger innovation pipelines

Connected Intelligence Sources

Patent IntelligenceScientific LiteratureClinical TrialsCompany IntelligenceMarket IntelligenceNews & Regulatory

Smarter Decisions

  • Discover breakthrough opportunities
  • Monitor emerging technologies
  • Identify white-space
  • Validate scientific direction
  • Reduce research risk
75%
Faster Research
80%
Lower Research Costs
6
Intelligence Domains
360°
Connected Intelligence
Start your intelligence journey

Stop guessing.
Start knowing.

Get a personalised 15-minute walkthrough of Neurorbis — built around your team's technology domain, research priorities, and IP strategy.

Connecting patents, scientific literature, clinical trials, companies, market intelligence, and news into one AI-powered technology intelligence platform.

Trusted by R&D & IP Teams75% Faster DecisionsEnterprise-Grade SecurityMulti-Source Intelligence